GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Implantica AG (OSTO:IMP A SDB) » Definitions » Interest Expense

Implantica AG (OSTO:IMP A SDB) Interest Expense : kr Mil (TTM As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Implantica AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Implantica AG's interest expense for the six months ended in . 20 was kr 0.00 Mil. Implantica AG does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in . 20.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Implantica AG's Operating Income for the six months ended in . 20 was kr 0.00 Mil. Implantica AG's Interest Expense for the six months ended in . 20 was kr 0.00 Mil. Implantica AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Implantica AG Interest Expense Historical Data

The historical data trend for Implantica AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Implantica AG Interest Expense Chart

Implantica AG Annual Data
Trend
Interest Expense

Implantica AG Semi-Annual Data
Interest Expense

Implantica AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.


Implantica AG  (OSTO:IMP A SDB) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Implantica AG's Interest Expense for the six months ended in . 20 was kr0.00 Mil. Its Operating Income for the six months ended in . 20 was kr0.00 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in . 20 was kr0.00 Mil.

Implantica AG's Interest Coverage for the quarter that ended in . 20 is calculated as

Implantica AG had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.


Implantica AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Aeulestrasse 45, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing advanced technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected, product pipeline based partly on its two platform technologies. Its lead product, RefluxStop, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results.

Implantica AG Headlines

No Headlines